Skip to main content
Retour
TEVA logo

Teva Pharmaceutical Industries Limited

Qualité des données : 100%
TEVA
NYSE Healthcare Drug Manufacturers - Specialty & Generic
28,77 €
▲ 0,04 € (0,14%)
Cap. Boursière : 33,51B
Fourchette du Jour
28,65 € 29,39 €
Fourchette 52 Semaines
12,47 € 37,35 €
Volume
4 106 809
Moyenne 50J / 200J
32,63 € / 23,84 €
Clôture Précédente
28,73 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E 23,8 0,4
P/B 4,2 2,9
ROE % 21,2 3,7
Net Margin % 8,2 3,9
Rev Growth 5Y % 2,1 10,0
D/E 2,2 0,2

Objectif de Cours des Analystes

Hold
38,33 € +33.2%
Low: 35,00 € High: 41,00 €
P/E Prévisionnel
10,6
BPA Prévisionnel
2,70 €
Croissance BPA (est.)
+0,0%
CA Est.
17 B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 4,06 €
4,01 € – 4,12 €
19 B 1
FY2029 3,58 €
3,54 € – 3,64 €
18 B 1
FY2028 3,44 €
2,25 € – 4,45 €
18 B 3

Points Clés

Revenue grew 2,10% annually over 5 years — modest growth
ROE of 21,23% indicates high profitability
Debt/Equity of 2,20 — high leverage
Generating 1,15B in free cash flow
Cash machine — converts 81,42% of earnings into free cash flow
Capital efficient — spends only 2,90% of revenue on capex

Croissance

Revenue Growth (5Y)
2,10%
Revenue (1Y)4,31%
Earnings (1Y)N/A
FCF Growth (3Y)16,77%

Qualité

Return on Equity
21,23%
ROIC6,40%
Net Margin8,17%
Op. Margin12,50%

Sécurité

Debt / Equity
2,20
Current Ratio1,04
Interest Coverage2,35

Valorisation

P/E Ratio
23,76
P/B Ratio4,24
EV/EBITDA21,94
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4,31% Revenue Growth (3Y) 4,36%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 2,10% Earnings Growth (5Y) 35,60%
Profitability
Revenue (TTM) 17,26B Net Income (TTM) 1,41B
ROE 21,23% ROA 3,46%
Gross Margin 51,79% Operating Margin 12,50%
Net Margin 8,17% Free Cash Flow (TTM) 1,15B
ROIC 6,40% FCF Growth (3Y) 16,77%
Safety
Debt / Equity 2,20 Current Ratio 1,04
Interest Coverage 2,35 Dividend Yield 0,00%
Valuation
P/E Ratio 23,76 P/B Ratio 4,24
P/S Ratio 1,94 PEG Ratio -0,14
EV/EBITDA 21,94 Dividend Yield 0,00%
Market Cap 33,51B Enterprise Value 47,33B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 17,26B 16,54B 15,85B 14,93B 15,88B
Net Income 1,41B -1,64B -559,00M -2,45B 417,00M
EPS (Diluted) 1,20 -1,45 -0,50 -2,20 0,38
Gross Profit 8,94B 8,06B 7,65B 6,97B 7,59B
Operating Income 2,16B -303,00M 433,00M -2,20B 1,72B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40,75B 39,33B 43,48B 44,01B 47,67B
Total Liabilities 32,83B 33,61B 35,35B 35,41B 36,42B
Shareholders' Equity 7,91B 5,37B 7,51B 7,80B 10,28B
Total Debt 17,38B 18,08B 20,15B 21,56B 23,46B
Cash & Equivalents 3,56B 3,30B 3,23B 2,80B 2,17B
Current Assets 13,95B 12,55B 12,49B 12,05B 12,57B
Current Liabilities 13,46B 12,80B 12,25B 11,47B 11,03B